fbpx COVID-19 (Coronavirus): ADB's Response | Asian Development Bank

COVID-19 (Coronavirus): ADB's Response

ADB is supporting its developing members in responding to the COVID-19 pandemic through finance, knowledge, and partnerships.

In the Spotlight

Health Security Interventions for COVID-19 Response: Guidance Note

Publication | 16 September 2022

Health Security Interventions for COVID-19 Response: Guidance Note

This guidance note is designed to help developing member countries of the Asian Development Bank strengthen their health systems and security as they recover from the impact of COVID-19.

Your Questions Answered: How Has the Pandemic Affected Asia’s Poor?

Blog Entry | 31 August 2022

Your Questions Answered: How Has the Pandemic Affected Asia’s Poor?

ADB statisticians Arturo Martinez and Joseph Bulan answer questions about how the pandemic has affected poverty in Asia, based on their research for Key Indicators for Asia and the Pacific 2022.

Informal Services in Asian Cities: Lessons for Urban Planning and Management from the COVID-19 Pandemic

Publication | 1 September 2022

Informal Services in Asian Cities: Lessons for Urban Planning and Management from the COVID-19 Pandemic

This book explores urban informality in Asian cities and looks how the informal sector's contribution to inclusive and sustainable growth can be enhanced.

ADB’s COVID-19 Response for Developing Asia Surpasses $20 Billion

Article | 13 September 2021

ADB’s COVID-19 Response for Developing Asia Surpasses $20 Billion

ADB’s committed assistance to help its developing member countries address the COVID-19 pandemic including vaccination support has surpassed $20 billion

ADB’s COVID-19 response consists of a $20 billion package announced in April 2020 and the $9 billion Asia Pacific Vaccine Access Facility (APVAX) announced in December 2020.

ADB’s initial $20 billion COVID-19 response package supports its developing member countries in countering the severe macroeconomic and health impacts caused by COVID-19, including $2.5 billion in concessional and grant resources, as well as $2 billion earmarked for the private sector (non-sovereign).

ADB's $9 billion APVAX vaccine initiative offers rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.

Committed Amount is the financing approved by ADB's Board of Directors or Management for which the legal agreement has been signed by the borrower, recipient, or the investee company and ADB.
*Projects may be listed in more than one country or subregion. The number of projects excludes short-term finance transactions under the Trade Finance, Supply Chain Finance, and Microfinance Programs.

News and Multimedia   Subscribe to our newsletter

Publications and Documents


Milestones

Made with Flourish